Cencora (COR) Aperçu de l'action
Cencora, Inc. achète et distribue des produits pharmaceutiques aux États-Unis et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 2/6 |
| Performances passées | 5/6 |
| Santé financière | 4/6 |
| Dividendes | 4/6 |
Récompenses
Analyse des risques
COR Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cencora, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$321.57 |
| Plus haut sur 52 semaines | US$377.54 |
| Plus bas sur 52 semaines | US$244.82 |
| Bêta | 0.57 |
| Variation sur 1 mois | 2.47% |
| Variation sur 3 mois | 14.26% |
| Variation sur 1 an | 6.30% |
| Variation sur 3 ans | 80.36% |
| Variation sur 5 ans | 160.44% |
| Évolution depuis l'introduction en bourse | 10,789.14% |
Nouvelles et mises à jour récentes
COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes
Analysts now cite a $10 rise in their Cencora price target to $330, reflecting updated views on fair value, discount rate, revenue growth assumptions and profit margin outlooks, while still applying a similar future P/E framework. What’s in the News for Cencora Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth.
COR: Expanded Buybacks And Higher 2026 EPS Guidance Will Support Long-Term Upside
Analysts have adjusted their price target for Cencora to $372.58 from $350.58, citing updated assumptions for discount rates, profit margins, and future P/E multiples in their valuation work. What's in the News for Cencora Cencora reported a strong fiscal third quarter with revenue growth and higher adjusted diluted EPS, and raised its 2026 adjusted EPS guidance range.Recent updates
COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes
Analysts now cite a $10 rise in their Cencora price target to $330, reflecting updated views on fair value, discount rate, revenue growth assumptions and profit margin outlooks, while still applying a similar future P/E framework. What’s in the News for Cencora Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth.COR: Expanded Buybacks And Higher 2026 EPS Guidance Will Support Long-Term Upside
Analysts have adjusted their price target for Cencora to $372.58 from $350.58, citing updated assumptions for discount rates, profit margins, and future P/E multiples in their valuation work. What's in the News for Cencora Cencora reported a strong fiscal third quarter with revenue growth and higher adjusted diluted EPS, and raised its 2026 adjusted EPS guidance range.COR: Fair View Will Weigh Nucleus Rollout, Cell Therapy And Legal Risk
Analysts now cite slightly firmer revenue growth, profit margin assumptions and a higher future P/E, which together support a refreshed Cencora fair value estimate increasing from $310 to $320. What’s in the News for Cencora Cencora launched a multi site pilot of its enhanced Nucleus inventory management solution for specialty physician practices, combining updated hardware and software to support medication workflow efficiency, visibility and control.Cencora: Specialty Infrastructure Is Rewriting The Distributor Model
Summary Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth. Execution risks include integration of acquisitions, increased leverage, regulatory scrutiny, and high customer concentration, but specialty platform buildout is expected to deepen margins and retention. Read the full article on Seeking AlphaCOR: Fair Value View Will Weigh Nucleus Rollout And Cell Therapy Partnership
Analysts have raised their Cencora price target from $288.21 to $310.00, reflecting updated views on fair value, revenue, profit margins, and future P/E assumptions. What’s in the News for Cencora Cencora announced a multi-site pilot of its enhanced Nucleus inventory management solution for specialty physician practices, with deployment planned in phases across more than 20 practice sites.COR: Insider Buying And Fair Value View Will Shape Upcoming Share Performance
Analysts have nudged their price target for Cencora higher from $280.00 to about $288.21, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What’s in the News for Cencora Cencora stock moved 3.6% higher on June 23, 2026, alongside commentary that the shares are viewed as modestly undervalued relative to one intrinsic value estimate and supported by what sources describe as solid business fundamentals.Cencora (COR) Stock Could Be 20% Below Fair Value On Margin Growth Narrative
Cencora (COR) stock has drawn investor attention after recent trading performance, with the share price closing at $281.43. The move comes alongside mixed short term returns and a longer multi year track record. See our latest analysis for Cencora. Recent trading puts Cencora’s 30 day share price return at 9.20%, yet the stock is still down 16.95% year to date. Longer term total shareholder returns over three and five years remain positive, suggesting recent momentum is rebuilding after a...COR: Buybacks And New CFO Appointment Will Support Long Term Upside
Analysts have modestly reduced their price target on Cencora to $350.58 from $356.83. This reflects slightly updated views on fair value and future P/E assumptions.COR: Buybacks And New CFO Will Support Long Term Upside
Analysts now estimate Cencora's fair value at $356.83 per share, down from $373.08. This change reflects updated assumptions around slightly slower revenue growth, a modestly lower profit margin outlook, and a small shift in future P/E expectations.Specialty And AI Investments Will Shape A Stable Yet Constrained Future Trajectory
Catalysts About Cencora Cencora is a pharmaceutical services company that supports manufacturers, health systems, physician practices and pharmacies across the global pharmaceutical supply chain. What are the underlying business or industry changes driving this perspective?COR: Share Repurchases And CFO Transition Will Support Long Term Upside
Analysts now estimate Cencora’s fair value at about $373, down from roughly $403. This reflects slightly higher assumed discount rates and a lower future P/E multiple, partly offset by a marginally stronger profit margin profile in their updated models.COR: CFO Transition And Disciplined Buybacks Will Support Long-Term Upside
Analysts have trimmed their price target on Cencora by about $5 to reflect slightly updated assumptions around fair value, revenue growth, profit margins, and future P/E, while still viewing the shares through a similar overall framework. What's in the News Cencora plans a leadership change, with long serving Chief Financial Officer James F.COR: Rare Disease Collaborations And Distribution Reach Will Support Long-Term Upside
Analysts have kept their price target for Cencora steady at $407.92, citing only very small tweaks to inputs like revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the business. What's in the News Cencora announced that Chief Financial Officer James F.COR: Rare Disease Partnerships Will Support Long-Term Upside For Capital Markets Access
Analysts have adjusted their fair value estimate for Cencora to about $408 from $410, reflecting small tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E rather than a major shift in the story. What's in the News Cencora plans for Chief Financial Officer James F.COR: Capital Markets And Rare-Disease Services Will Support Long-Term Upside
Analysts now place Cencora's fair value at $410.00, up from $403.79. This change reflects small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates in their models.COR: 3PL Expansion And M&A Options Will Shape Balanced Long-Term Upside
Analysts have nudged their price target for Cencora higher to about $404 from roughly $400, citing refreshed assumptions around revenue growth, profitability and a modestly higher future P/E multiple. What's in the News Cencora is expanding its third party logistics capabilities in the United States and Europe, including adding NextPharma Logistics across Germany, Austria and Switzerland and planning a new 3PL facility in Italy in 2026, alongside increased cold chain capacity across its European network (company announcement).Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Cencora, Inc.'s ( NYSE:COR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...COR: Buybacks And 3PL Expansion Will Support Long-Term Upside Potential
Analysts have nudged their projected fair value for Cencora to $399.80 from $396.80, citing updated assumptions around revenue growth, profit margins, the discount rate and a slightly lower future P/E multiple. What's in the News Cencora completed a share repurchase program totaling 4,895,419 shares, or 2.49% of shares, for US$1,118.1m under the buyback announced on May 1, 2024 (Buyback Tranche Update).COR: Global 3PL Expansion And Logistics Investments Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about US$397 from roughly US$388. This reflects refreshed assumptions on revenue growth, profit margins and future P/E levels in their models.COR: Global 3PL Buildout And Higher Dividend Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about $388, citing slightly lower modeled revenue growth, a modestly stronger profit margin, and a small uptick in assumed future P/E as key drivers of the updated view. What's in the News Cencora announced investments to expand its third party logistics capabilities in the United States and Europe, including broader specialty logistics services for pharmaceutical companies worldwide.COR: Global 3PL Expansion And Dividend Increases Will Offset Goodwill Impairment Risks
Analysts have slightly raised their price target on Cencora, increasing fair value by about 1.8 dollars per share as they factor in marginally stronger projected revenue growth, a modestly higher long term profit margin, and a steady future earnings multiple. What's in the News Cencora is making major investments to expand its third party logistics network, including a new 500,000 square foot 3PL facility in Texas by 2028 and a tripling of ultra low and cryogenic storage capacity in the United States, to support growing demand for specialty medicines such as cell and gene therapies (company announcement).COR: Automated Distribution Expansion And Margins Will Balance Storage And Dividend Risks
Analysts have modestly raised their price target for Cencora, increasing the estimated fair value by $2.71 to $384.79. This adjustment is based on slight improvements in profit margin expectations and valuation multiples.COR: Automated Expansion And Margin Gains Will Offset Ongoing Legal Risks
Analysts have raised their price target for Cencora, increasing the estimated fair value from $338.29 to $382.07. They cite strengthened profit margin expectations, even though there is a slightly higher discount rate and moderated revenue growth forecasts.COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution
Analysts have raised their price target for Cencora by $5 to $338.29. They cite updated forecasts for slightly lower near-term revenue growth, but a stronger overall fair value assessment.Digital Infrastructure And Specialty Services Will Redefine Healthcare Delivery
With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29. What's in the News Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.Rendement pour les actionnaires
| COR | US Healthcare | US Marché | |
|---|---|---|---|
| 7D | -2.8% | -1.8% | -0.9% |
| 1Y | 6.3% | 15.7% | 14.2% |
Rendement vs Industrie: COR a sous-performé le secteur US Healthcare qui a rapporté 15.7 % au cours de l'année écoulée.
Rendement vs marché: COR a sous-performé le marché US qui a rapporté 14.2 % au cours de l'année écoulée.
Volatilité des prix
| COR volatility | |
|---|---|
| COR Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Cours de l'action stable: COR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de COR ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1871 | 49,000 | Bob Mauch | www.cencora.com |
Cencora, Inc. achète et distribue des produits pharmaceutiques aux États-Unis et dans le monde entier. Le segment U.S. Healthcare Solutions distribue des produits pharmaceutiques génériques et injectables, des produits de santé en vente libre, des fournitures et équipements de soins à domicile et des services connexes aux hôpitaux de soins aigus et aux systèmes de santé, aux pharmacies de détail indépendantes et de chaîne, aux pharmacies de vente par correspondance, aux cliniques médicales, aux pharmacies de soins de longue durée et de sites alternatifs, et à d'autres clients ; distribue du plasma et d'autres produits sanguins, des vaccins et d'autres produits pharmaceutiques spécialisés ; fournit des services de gestion de pharmacie, de dotation en personnel et d'autres services de conseil ; des logiciels de gestion de l'approvisionnement aux fournisseurs de soins de santé de détail et institutionnels ; des solutions d'emballage aux fournisseurs de soins de santé institutionnels et de détail ; des services de soutien aux essais cliniques, de post-approbation des produits et de soutien à la commercialisation ; des services d'analyse de données, de recherche sur les résultats et d'autres services pour les fabricants de produits biotechnologiques et pharmaceutiques ; des produits pharmaceutiques, des vaccins, des parasiticides, des diagnostics, des ingrédients de micro-alimentation et d'autres produits pour les marchés des animaux de compagnie et de production ; des services de force de vente aux fabricants ; et d'autres services aux médecins spécialisés dans divers états pathologiques, tels que l'oncologie, ainsi qu'à d'autres fournisseurs de soins de santé, y compris les hôpitaux et les cliniques de dialyse.
Cencora, Inc. Résumé des fondamentaux
| COR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$61.36b |
| Bénéfices(TTM) | US$2.62b |
| Recettes(TTM) | US$332.77b |
Le site COR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| COR compte de résultat (TTM) | |
|---|---|
| Recettes | US$332.77b |
| Coût des recettes | US$319.59b |
| Marge brute | US$13.18b |
| Autres dépenses | US$10.56b |
| Les revenus | US$2.62b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 13.75 |
| Marge brute | 3.96% |
| Marge bénéficiaire nette | 0.79% |
| Ratio dettes/capitaux propres | 361.9% |
Quelles ont été les performances à long terme de COR?
Voir les performances historiques et les comparaisonsDividendes
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/13 04:39 |
| Cours de l'action en fin de journée | 2026/09/11 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/09/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Cencora, Inc. est couverte par 31 analystes. 13 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |